These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 10910797)

  • 21. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.
    Moritz S; Veckenstedt R; Andreou C; Bohn F; Hottenrott B; Leighton L; Köther U; Woodward TS; Treszl A; Menon M; Schneider BC; Pfueller U; Roesch-Ely D
    JAMA Psychiatry; 2014 Oct; 71(10):1103-11. PubMed ID: 25103718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up.
    Granholm E; McQuaid JR; McClure FS; Link PC; Perivoliotis D; Gottlieb JD; Patterson TL; Jeste DV
    J Clin Psychiatry; 2007 May; 68(5):730-7. PubMed ID: 17503982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia.
    Velligan DI; Diamond P; Mueller J; Li X; Maples N; Wang M; Miller AL
    Psychiatry Res; 2009 Jul; 168(2):94-101. PubMed ID: 19523690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication.
    Sensky T; Turkington D; Kingdon D; Scott JL; Scott J; Siddle R; O'Carroll M; Barnes TR
    Arch Gen Psychiatry; 2000 Feb; 57(2):165-72. PubMed ID: 10665619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test.
    Eack SM; Greeno CG; Pogue-Geile MF; Newhill CE; Hogarty GE; Keshavan MS
    Schizophr Bull; 2010 Mar; 36(2):370-80. PubMed ID: 18648021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.
    Kwon JS; Choi JS; Bahk WM; Yoon Kim C; Hyung Kim C; Chul Shin Y; Park BJ; Geun Oh C
    J Clin Psychiatry; 2006 Apr; 67(4):547-53. PubMed ID: 16669719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A program for relapse prevention in schizophrenia: a controlled study.
    Herz MI; Lamberti JS; Mintz J; Scott R; O'Dell SP; McCartan L; Nix G
    Arch Gen Psychiatry; 2000 Mar; 57(3):277-83. PubMed ID: 10711914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project.
    Jackson HJ; McGorry PD; Killackey E; Bendall S; Allott K; Dudgeon P; Gleeson J; Johnson T; Harrigan S
    Psychol Med; 2008 May; 38(5):725-35. PubMed ID: 18005494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated treatment vs. treatment-as-usual for recent onset schizophrenia; 12 year follow-up on a randomized controlled trial.
    Sigrúnarson V; Gråwe RW; Morken G
    BMC Psychiatry; 2013 Jul; 13():200. PubMed ID: 23898805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new computerized cognitive and social cognition training specifically designed for patients with schizophrenia/schizoaffective disorder in early stages of illness: A pilot study.
    Fernandez-Gonzalo S; Turon M; Jodar M; Pousa E; Hernandez Rambla C; García R; Palao D
    Psychiatry Res; 2015 Aug; 228(3):501-9. PubMed ID: 26163731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
    Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
    Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial.
    Eack SM; Hogarty GE; Cho RY; Prasad KM; Greenwald DP; Hogarty SS; Keshavan MS
    Arch Gen Psychiatry; 2010 Jul; 67(7):674-82. PubMed ID: 20439824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TDCS produces incremental gain when combined with working memory training in patients with schizophrenia: A proof of concept pilot study.
    Nienow TM; MacDonald AW; Lim KO
    Schizophr Res; 2016 Apr; 172(1-3):218-9. PubMed ID: 26852404
    [No Abstract]   [Full Text] [Related]  

  • 36. Compensatory cognitive training for psychosis: effects in a randomized controlled trial.
    Twamley EW; Vella L; Burton CZ; Heaton RK; Jeste DV
    J Clin Psychiatry; 2012 Sep; 73(9):1212-9. PubMed ID: 22939029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: Effects on adjustment of patients.
    Hogarty GE; Greenwald D; Ulrich RF; Kornblith SJ; DiBarry AL; Cooley S; Carter M; Flesher S
    Am J Psychiatry; 1997 Nov; 154(11):1514-24. PubMed ID: 9356558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): a study protocol for a centrally randomised, observer-blinded multi-centre clinical trial.
    Vesterager L; Christensen TØ; Olsen BB; Krarup G; Forchhammer HB; Melau M; Gluud C; Nordentoft M
    Trials; 2011 Feb; 12():35. PubMed ID: 21306612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compensatory cognitive training for psychosis: who benefits? Who stays in treatment?
    Twamley EW; Burton CZ; Vella L
    Schizophr Bull; 2011 Sep; 37 Suppl 2(Suppl 2):S55-62. PubMed ID: 21860048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.